PRNewsWire
15 Apr 2026, 13:00 UTC · 27w ago
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Conducting Sham Clinical Trials: Levi & Korsinsky
Impact · against what's priced in
Soleno Therapeutics faces significant binary risk following allegations of clinical trial fraud and concealed safety risks for its sole commercial product, VYKAT XR. These claims directly threaten the regulatory foundation of the drug's FDA approval and its commercial viability.
- SLNO−0.80
No priced-in read yet





